Eunice Yuen

First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

Christophe Massard, A. Ázaro, Jean‐Charles Soria et al. · Annals of Oncology · 2018 · 159 citations · Full text

ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine

Shripad V. Bhagwat, William T. McMillen, Shufen Cai et al. · Molecular Cancer Therapeutics · 2019 · 101 citations · Full text

A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer

Shubham Pant, Suzanne F. Jones, Carla Kurkjian et al. · European Journal of Cancer · 2016 · 89 citations

The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects

David S. Small, Prajakti A. Kothare, Eunice Yuen et al. · European Journal of Clinical Pharmacology · 2009 · 72 citations

Pharmacological Study, Healthy Chinese, Pharmacology +6

Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma

Caroline Even, Ulrik Lassen, Jaime R. Merchan et al. · Investigational New Drugs · 2019 · 69 citations · Full text